Table 1.
Characteristic | PD | Controls | Difference (P Value) |
---|---|---|---|
N | 43 | 35 | |
Age (yr) | 57.5 ± 8.45 | 56.23 ± 7.83 | 0.5 |
Male Female | 35 8 | 27 8 | 0.64 |
H & Y stage | 1.91 ± 0.48 | n/a | |
Total MDS‐UPDRSa | 45.41 ± 17.22 | 3.17 ± 2.7 | <0.001 |
MDS‐UPDRS I | 6.91 ± 4.71 | 1.80 ± 2.08 | <0.001 |
MDS‐UPDRS II | 9.21 ± 6.10 | 0.23 ± 0.73 | <0.001 |
MDS‐UPDRS III | 27.67 ± 11.22 | 1.14 ± 1.06 | <0.001 |
MDS‐UPDRS IV | 1.63 ± 2.65 | 0 ± 0 | <0.001 |
MoCA | 26.86 ± 2.46 | 28.34 ± 1.35 | 0.001 |
Mean disease duration (yr) | 3.51 ± 2.86 | n/a | |
Proportion of patients taking dopaminergic medication | 81% | n/a | |
Experiencing fluctuations (%)b | 37% (30% experience at least a slight impact) | n/a | |
MDS‐UPDRS‐defined TD and PIGD PD subtypes | 29 TD; 9 PIGD; 5 indeterminate | n/a | |
Experiencing dyskinesia (%)c | 9.3% | n/a |
Data are mean ± SD or proportions.
Total MDS‐UPDRS = MDS‐UPDRS I + MDS‐UPDSR II + MDS‐UPDRS III.
Proportion of patients with MDS‐UPDRS 4.3 “time spent in the off state >0.”
Proportion of patients with MDS‐UPDRS 4.1 “time spent with dyskinesia >0.” A total of 1 PD had functional impact of dyskinesias, indicated by MDS‐UPDRS 4.2 > 0.
TD, tremor dominant. n/a, not applicable.